Abdullah M. Khan

Hand signing hundreds of pages of #clinicaltrials data = time consuming, redundant, wasteful.

Nice work @Ashley_Rosko1 and @CancerNetwrk

Therapy for patients AND providers! @OSUCCC_James

@DrMarcosdelima Exactly my intentions :)

Dr Grever : here you see that I am trying to learn by proximity!!!

@beatalleukemia Watched the whole match on the flight only to miss the penalties getting luggage *smh*

Wow that does it for Brazil. #Heartstopper #ASH22 #WorldCup

@RashmiGMD @MdOzga @hem_derek @OSUWexMed @OSUCOM_WIM Thanks for organizing @RashmiGMD , fun #balling with you all again, @OSUHematology

Amazing basketball night!!! Look at these doctor athletes. Not only do we advocate for our patients to exercise. We exercise ourselves. Faculty Athletic Council!!!

@kplant_gnv @UFHealthCancer Congrats Kourtney!

Session 653 not working from home *groan* #ASH21 too late to fly to Atlanta?!

@RohitBishnoi_MD Congrats doc!!

It’s been long journey….. started way back with med school in India. wouldn’t have been possible without supporting wife, family, friends and mentors. 🙏🙏

@ManniMD1 @sassineghmd I know the numbers are very small but the inf outcomes of amp 1q treated with KRd are very puzzling

@sassineghmd Thanks for that great point. High risk patients have been underrepresented in every trial, so most of what we know is from subset analysis. ENDURANCE did enroll 4:14 and Gain 1q. Hard to drawn conclusions from ENDURANCE subset analysis for those subgroups.

So, the FORTE trial was recently published. This is a great trial, and there are many important lessons/concepts/questions that arise from this, which I wanted to highlight in this 🧵 sciencedirect.com/science/articl… #mmsm

@JoshuaRichterMD Congratulations!!

Woo hoo! Promotion came through 😀

@kplant_gnv Dr LaPlant!! Good luck with everything and I look forward to visiting you all in the near future

@Dr_AmerZeidan pubmed.ncbi.nlm.nih.gov/29785311/ And our case report @hemant_murthy

Thanks to all for responses. This actually turned out to be B-cell ALL. I also thought initially based on smear this would be myeloid, but this case illustrates why we should generally avoid treating by morphology (except for APL and emergencies) till we have flow confirmation

@andrewjohnsmd @MDAndersonNews Congrats doc!!

So incredibly excited to announce that I am headed to MD Anderson @MDAndersonNews for hematology/oncology fellowship! Absolutely could not have done this without the amazing support of so many people:

@lsarsour (and colleagues) excellent representation @PBS #NOTDONE

@Mohty_EBMT @szusmani @Carolina_Health @IMFmyeloma @theMMRF @MyelomaUK @MyelomaTeacher @TheIACH Congratulations @szusmani!

Congratulations Dr ⁦@szusmani⁩ . The ⁦whole myeloma community is very proud of you. You have contributed so much to advance the field and we are very grateful. ⁦@Carolina_Health⁩ ⁦@IMFmyeloma⁩ ⁦@theMMRF⁩ ⁦@MyelomaUK⁩ ⁦@MyelomaTeacher⁩ @theiach

@anatalemd Very sad news, she was an amazing colleague/teacher

It is with sadness that we communicate the passing of Dr. Anabella Moharita on Saturday 26, 2020. She will always be remembered for her kindness, generosity, and unwavering faith. The Lord has called her home. May she Rest In Peace

@JoshuaRichterMD Congrats doc!

Introducing Audrey Luna to the Twitter world. I typically post only about myeloma and medicine. But this is a reminder that the most important thing is family ☺️

Excellent Hematology Symposium organized by @kmaddmd and colleagues @OSUCCC_James

The chromosome 1q21 story (1/10): -Having extra copies of generally odd num. chromosomes constituents hyperdiploidy #mmsm , recognized as ‘HY’ in GEP based molecular classification. -Having 3 copies is called ‘gain 1q21’ -Having >=4 copies is called ‘amplification of 1q21’.